Cullinan Oncology LLC (CGEM) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Cullinan Oncology LLC (CGEM) has a cash flow conversion efficiency ratio of -0.126x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-46.05 Million) by net assets ($366.17 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See how many days can Cullinan Oncology LLC fund operations to measure how many days the company can operate on defensive assets alone.
Cullinan Oncology LLC - Cash Flow Conversion Efficiency Trend (2013–2025)
This chart illustrates how Cullinan Oncology LLC's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Cullinan Oncology LLC Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Cullinan Oncology LLC ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Mingyue Optical Lens Co.Ltd.
SHE:301101
|
N/A |
|
Guizhou Bailing Group Pharmaceutical Co Ltd
SHE:002424
|
0.092x |
|
Shenzhen Shengxunda Technology Co Ltd Class A
SHE:300518
|
0.020x |
|
Bowhead Specialty Holdings Inc.
NYSE:BOW
|
0.143x |
|
GMR Power and Urban Infra Limited
NSE:GMRP&UI
|
0.216x |
|
Zhejiang Whwh
SHG:600576
|
0.061x |
|
Hang Xiao Steel Structure Co Ltd
SHG:600477
|
0.025x |
|
Corticeira Amorim
LS:COR
|
0.036x |
Annual Cash Flow Conversion Efficiency for Cullinan Oncology LLC (2013–2025)
The table below shows the annual cash flow conversion efficiency of Cullinan Oncology LLC from 2013 to 2025. For the full company profile with market capitalisation and key ratios, see Cullinan Oncology LLC market cap and net worth.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $408.73 Million | $-175.75 Million | -0.430x | -74.69% |
| 2024-12-31 | $590.33 Million | $-145.30 Million | -0.246x | +16.80% |
| 2023-12-31 | $453.89 Million | $-134.28 Million | -0.296x | -24.96% |
| 2022-12-31 | $535.03 Million | $-126.66 Million | -0.237x | -131.86% |
| 2021-12-31 | $425.37 Million | $-43.43 Million | -0.102x | +31.30% |
| 2020-12-31 | $200.31 Million | $-29.77 Million | -0.149x | -128.38% |
| 2019-12-31 | $-39.91 Million | $-20.90 Million | 0.524x | -20.20% |
| 2018-12-31 | $-20.65 Million | $-13.55 Million | 0.656x | +64.77% |
| 2016-12-31 | $-574.85K | $-228.91K | 0.398x | +1962.80% |
| 2015-12-31 | $-1.24 Million | $-24.03K | 0.019x | -76.10% |
| 2014-12-31 | $-1.14 Million | $-91.72K | 0.081x | -88.70% |
| 2013-12-31 | $-1.00 Million | $-718.41K | 0.715x | -- |
About Cullinan Oncology LLC
Cullinan Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops therapies for autoimmune diseases and cancer in the United States. It engages in the development of CLN-978, a CD19xCD3 bispecific T cell engager for autoimmune diseases in Phase 1 clinical trials; Velinotamig, a BCMAxCD3 bispecific T cell in Phase 1 clinical trials in patients with autoimmune diseases; and CLN-049,… Read more